Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general overview [0.03%]
aflibercept、ranibizumab和bevacizumab的即将上市的生物类似药：一个总体概述
P Viola,V Testa,L Ferro Desideri et al.
P Viola et al.
Anti-vascular endothelial growth factors currently are the first-line treatment option for neovascular age-related macular degeneration (nAMD) and other retinal vascular disorders, and their clinical use is associated with high financial bu...
Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma [0.03%]
纳克他美单抗：一种用于治疗神经母细胞瘤的人源化抗糖脂二唾液酸神经节苷酯（抗GD2）单克隆抗体
L R Slatnick,A Jimeno,L Gore et al.
L R Slatnick et al.
Therapy for high-risk neuroblastoma (HR NBL) is comprised of multimodal therapy including chemotherapy, surgery, radiation therapy, myeloablative therapy followed by autologous hematopoietic stem cell transplant, and immunotherapy. GD2 is a...
S R Goldsmith,L Liu,F Covut
S R Goldsmith
Isatuximab is an IgG1 monoclonal antibody targeting CD38 that has received regulatory approval in combination regimens for patients with relapsed/refractory multiple myeloma. CD38 is an antigen with high surface expression on multiple myelo...
B Wang,C Wu,Q Zhong et al.
B Wang et al.
Multiple myeloma is the second most common hematologic malignancy worldwide. Despite the growing number of available therapeutic options and advances in the treatment since the 2000s, relapse of multiple myeloma is inevitable. Currently, th...
European Society of Cardiology (ESC) Congress 2021 (August 27-30, 2021 - Virtual Meeting) [0.03%]
2021年欧洲心脏病学会(ESC)大会(2021年8月27-30日-在线会议)
G Croasdell
G Croasdell
The 2021 Congress of the European Society of Cardiology (ESC) was again held as a digital experience, providing poster and oral sessions highlighting the latest developments in cardiovascular science, including therapeutics for a range of r...
Drug Information Association (DIA) 2021 Global Annual Meeting (June 26-July 1, 2021 - Virtual Meeting) [0.03%]
药物信息协会(DIA)2021年全球年会（2021年6月26日至7月1日-在线会议）
R Kaur
R Kaur
At the 57th Global Annual Meeting of the Drug Information Association (DIA), attendees met virtually for the second time to support the theme of 'Collaboration without Boundaries.' Sessions included presenters and speakers from regulatory a...
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions [0.03%]
塞普替尼治疗具有RET基因突变或融合的肺和甲状腺癌
H Zheng,Z-S Chen,J Li
H Zheng
Aberrations in oncogene RET (rearranged during transfection) have been found to be the cause of different kinds of malignancies, especially in lung and thyroid cancers. Targeted therapy of RET-altered cancers using multi-kinase inhibitors (...
C Engler,C Ebenbichler
C Engler
Cardiovascular disease is the most common cause of death worldwide and is mainly due to atherosclerosis. Elevated levels of low-density lipoprotein cholesterol (LDL-C) are the main risk factor for atherosclerosis. Treatment with existing th...
S R Goldsmith,N Foley,M A Schroeder
S R Goldsmith
Since its initial approval in 2015, daratumumab has had a tremendous impact on the treatment of multiple myeloma. It is a monoclonal antibody that targets CD38, an antigen with high surface expression on multiple myeloma cells. While it ini...
Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma [0.03%]
Tafasitamab治疗复发/难治性弥漫大B细胞淋巴瘤
Q Lu,H Huang,S Tang et al.
Q Lu et al.
Diffuse large B-cell lymphoma (DLBCL) is a common lymphoproliferative and invasive disease. The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, doxorubicin, vincristi...